Hendley & Co. Inc. Decreases Stock Position in AstraZeneca PLC $AZNCF

Hendley & Co. Inc. decreased its position in AstraZeneca PLC (OTCMKTS:AZNCF) by 50.0% in the 1st quarter, Holdings Channel reports. The fund owned 32,377 shares of the company’s stock after selling 32,428 shares during the period. AstraZeneca accounts for 2.4% of Hendley & Co. Inc.’s holdings, making the stock its 19th biggest holding. Hendley & Co. Inc.’s holdings in AstraZeneca were worth $6,385,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AZNCF. Town & Country Bank & Trust CO dba First Bankers Trust CO purchased a new position in shares of AstraZeneca in the first quarter valued at $1,351,000. Monetary Management Group Inc. purchased a new stake in AstraZeneca during the 4th quarter worth $1,097,000. Seven Mile Advisory purchased a new stake in AstraZeneca during the 4th quarter worth $738,000. L & S Advisors Inc acquired a new position in AstraZeneca in the 4th quarter worth $14,863,000. Finally, Oarsman Capital Inc. acquired a new position in AstraZeneca in the 4th quarter worth $5,027,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

OTCMKTS:AZNCF opened at $187.10 on Tuesday. The firm has a 50-day moving average of $187.10 and a two-hundred day moving average of $186.10. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.